Comprehensive Heterocyclic ChemistryA. R. Katrizky and C. W. Rees,
Eds; Pergamon: Oxford, 1984; Vol 1., Ch. 1/06; (c) J. T. Sharp, in
Comprehensive Heterocyclic ChemistryA. R. Katrizky and C. W. Rees,
Eds; Pergamon: Oxford, 1984; Vol 7., Ch. 5/18; (d) R. Baldessarini, in
The Pharmacologic Basis of TherapeuticsA. G. Gilman, L. S. Goodman,
T. W. Ralland and F. Murand, ed.; MacMillan: New York, 1985; Vol 1,
pp 391–413; (e) R. Ramajayan, R. Girdhar and M. R. Yadav, Mini-Rev.
Med. Chem., 2007, 7, 793–812.
2 Y. Shimada, N. Taniguchi, A. Matsuhisa, K. Sakamoto, T. Yatsu and
A. Tanaka, Chem Pharm. Bull, 2000, 48, 1644–1651.
3 A. L. Sabb, R. L. Vogel, G. S. Welmaker, J. E. Sabalski, J. Coupet, J.
Dunlop, S. Rosenzweig-Lipson and B. Harrison, Bioorg. Med. Chem.
Lett., 2004, 14, 2603–2607.
4 See for example: B. Petit-Demouliere, F. Masse, N. Cogrel, M. Hascoet
and M. Bourin, Behav. Brain Res., 2009, 204, 200–205.
5 D. E. Thurston, in Molecular Aspects of Anticancer Drug-DNA
InteractionsS. Needle and M. J. Waring, ed.; The Macmillan Press Ltd.:
London, UK, 1993; Vol. 1, pp 54–88.
6 A. Kamal, N. Shankaraiah, S. Prabhakar, C. R. Reddy, N. Markandeya,
K. Laxma and X. Devaiah, Bioorg. Med. Chem. Lett., 2008, 18, 2434–
2439.
16 See for example: Y. Ohta, H. Chiba, S. Oishi, N. Fujii and H. Ohno,
Org. Lett., 2008, 10, 3535–3538 and references cited therein.
17 Pirenzepine is a pyridobenzodiazepine with multiple biological activ-
ities. See for example: B. Ilien, N. Glasser, J.-P. Clamme, P. Didier, E.
Piemont, R. Chinnappan, S. B. Daval, J.-L. Galzi and Y. Mely, J. Biol.
Chem., 2009, 284, 19533–19543.
18 (a) B. Insuasty, F. Orozco, J. Quiroga, R. Abonia, M. Nogueras and
J. Cobo, Eur. J. Med. Chem., 2008, 43, 1955–1962; (b) B. Insuasty,
F. Orozco, C. Lizarazu, J. Quiroga, R. Abonia, M. Hursthouse, M.
Nogueras and J. Cobo, Bioorg. Med. Chem., 2008, 16, 8492–8500.
19 A. Guram, R. A. Rennels and S. L. Buchwald, Angew. Chem., Int. Ed.
Engl., 1995, 34, 1348–1350.
20 J. Louis and J. F. Hartwig, Tetrahedron Lett., 1995, 36, 3609–3612.
21 For a revision on the Buchwald–Hartwig reaction see: (a) D. Prim,
J.-M. Campagne, D. Joseph and B. Andrioletti, Tetrahedron 2002, 58,
2041–2075; (b) A. R. Muci and S. L. Buchwald, Top. Curr. Chem., 219,
131–209.
22 The Buchwald–Hartwig amination from an industrial point of view is
described in: B. Schlummer and U. Scholz, Adv. Synth. Catal., 2004,
346, 1599–1626.
23 The Buchwald–Hartwig cross-coupling reaction has been used in
pharmaceutical synthesis, natural product synthesis, and material
science. A very good revision of these applications in: D. S. Surry and
S. L. Buchwald, Angew. Chem., Int. Ed., 2008, 47, 6338–6361.
24 The synthesis of indoles or indolines by the Buchwald–Hartwig
aimantion is described in: (a) J. A. Brown, Tetrahedron Lett., 2000,
41, 1623–1626; (b) M. Watanabe, T. Yamamoto and M. Nishiyama,
Angew. Chem., Int. Ed., 2000, 39, 2501–2504; (c) J. P. Wolfe, R. A.
Rennels and S. L. Buchwald, Tetrahedron, 1996, 52, 7525–7546; (d) B. H.
Yang and S. L. Buchwald, Org. Lett., 1999, 1, 35–37; (e) Preparation of
indazoles by this methodology: Y.-M. Zhu, Y. Kiyu and H. Katayama,
Tetrahedron Lett., 2002, 43, 3577–3580; (f) J. J. Song and N. K. Yee,
Tetrahedron Lett., 2001, 42, 2937–2940; (g) J. J. Song and N. K. Yee, Org.
Lett., 2000, 2, 519–521; (h) The access to phenazines by this procedure is
described in: T. Emoto, N. Kubosaki, Y. Yamagiwa and T. Kamikawa,
Tetrahedron Lett., 2000, 41, 355–358; (i) Synthesis of benzimidazoles:
C. T. Brian and S. A. Brunton, Tetrahedron Lett., 2002, 43, 1893–1895;
(j) T. Iwaki, A. Yasuhara and T. Sakamoto, J. Chem. Soc., Perkin
Trans. 1, 1999, 1505–1510; (k) C. Venkatesh, G. S. M. Sundaram, H.
Ila and H. Junjappa, J. Org. Chem., 2006, 71, 1280–1283; (l) C. T. Brian
and J. T. Steer, J. Org. Chem., 2003, 68, 6814–6816; (m) Synthesis of
oxazepines an thiazepines: B. J. Margolis, J. J. Swisorski and B. N.
Rogers, J. Org. Chem., 2003, 68, 644–647; (n) Preparation of imidazoles
and its benzo- and aza- analogues: K. T. J. Loones, B. U. W. Maes, R. A.
Dommisse and G. L. F. Lemiere, Chem. Commun., 2004, 2466–2467;
(o) Preparation of oxindoles: F. Bonnaterre, M. Bois-Choussy and J.
Zhu, Org. Lett., 2006, 8, 4351–4354.
25 An elegant synthetic route for the access to a series of dibenzodiazepine-
11-ones based on an intramolecular amination process was reported
in: E. M. Beccalli, G. Broggini, G. Paladino and C. Zoni, Tetrahedron,
2005, 61, 61–68.
26 For the synthesis of 1,4-benzodiazepine-2,5-diones by the combination
of an Ugi multicomponent reaction and a palladium catalyzed N-
arylation, see: (a) G. Cuny, M. Bois-Choussy and J. Zhu, J. Am. Chem.
Soc., 2004, 126, 14475–14484; (b) C. Kalinsky, M. Umkehrer, G. Ross,
J. Kolb, C. Burdack and W. Hiller, Tetrahedron Lett., 2006, 47, 3423–
3426.
27 A recent application of the modified Vilsmeier-Haak reagent
DMFDMA is described in: (a) F. M. Abdelrazek and N. H. Metwally,
Synth. Commun., 2009, 39, 4088–4099; (b) Ortho-bromoarylhydrazines
4b–d were prepared by diazotization/reduction of the corresponding
anilines. For a related procedure, see: D. Gennet, P. Michel and A.
Rassat, Synthesis, 2000, 447–451.
7 (a) J. Ip, J. X. Wilson and J. P. Uetrecht, Chem. Res. Toxicol., 2008, 21,
869–873; (b) A. Bali, S. Malhotra, H. Dhir, A. Kumar and A. Sharma,
Bioorg. Med. Chem. Lett., 2009, 19, 3041–3044.
8 (a) C. Lamberth, Heterocycles, 2007, 71, 1467–1502; (b) W. Zheng,
S. R. Yates and S. K. Papiernik, J. Agric. Food Chem., 2008, 56, 7367–
7372.
9 Diaryl heterocycles in general are a selective class of COX-2 inhibitors.
See: P. Chavatte, S. Yous, C. Marot, N. Baurin and D. Lesieur, J. Med.
Chem., 2001, 44, 3223–3230.
10 (a) J. Kelsey, O. Harris and J. Cassin, Behav. Brain Res., 2009, 203,
304–307; (b) V. K. Kotagiri, S. Suthrapu, J. M. Reddy, C. P. Rao, V.
Bollugoddu, A. Bhattacharya and R. Bandichhor, Org. Process Res.
Dev., 2007, 11, 910–912.
11 (a) Other applications of Celecoxib include treatment of preterm labour,
osteoarthritis and rheumatoid arthritis, inflammatory bowel disease
and duodenal polyposis in familial adenomatous polyposis. See C. S.
Stika, G. A. Gross, G. Leguizamon, S. Gerber, R. Levy, A. Mathur,
L. M. Bernhard, D. M. Nelson and Y. Sadovsky, Am. J. Obstet.
Gynecol., 2002, 187, 653–660; (b) K. Dilger, C. Herrlinger, J. Peters,
H. W. Seyberth, H. Scheweer and U. Klotz, J. Clin. Pharmacol., 2002,
42, 985–994; (c) K. M. Woessner, R. A. Simon and D. D. Stevenson,
Arthritis Rheum., 2002, 46, 2201–2206.
12 This type of compounds comprises a class of non-steroidal anti-
inflammatory drugs (NSAID). See for example: (a) J. P. O’Connor
and T. Lysz, Drugs of Today, 2008, 44, 693–709; (b) U. Taeuber, Drugs
Exp. Clin. Res., 1990, 16, 7–15; (c) A. G. Habeeb, P. N. Praveen and
E. E. Knaus, J. Med. Chem., 2001, 44, 3039–3042; (d) H. Liu, X. Huang,
J. M. Shen, X. Luo, M. Li, B. Xiong, G. Chen, J. Shen, Y. Yang, H.
Jiang and K. Chen, J. Med. Chem., 2002, 45, 4816–4827; (e) S. K.
Singh, S. Vobbalareddy, S. Shivaramakrishna, A. Krishnamraju, S. A.
Rajjak, S. R. Casturi, V. Akhila and Y. K. Rao, Bioorg. Med. Chem.
Lett., 2004, 14, 1683–1688; (f) A. Weber, A. Casini, A. Heine, D. Kuhn,
C. T. Sapuran, A. Scozzafava and G. Klebe, J. Med. Chem., 2004, 47,
550–557.
13 Narayama et al. reported the synthesis and anticonvulsant activity
of a series of triazolo-fused benzodiapepine derivatives. See: (a) B.
Narayana, K. K. V. Raj, B. V. Ashalatha and N. S. Kumari, Eur. J. Med.
Chem., 2006, 41, 417–422; (b) Later, the same authors described the
antianxiety properties and the anticancer activity of some of these
derivatives: K. K. V. Raj, B. Narayana, N. S. Kumari, B. V. Ashalatha
and B. K. Sarojini, Journal of Pharmacology and Toxicology, 2006, 1,
471–477.
14 It is well known the pharmacological activity of some thieno-fused
diazepines such as clotiazepam, brotizolam and etizolam. See for
example: V. Lisowsky, F. Fabis, A. Pierre, D. H. Caignard, P. Renard
and S. Rault, J. Enzyme Inhib. Med. Chem., 2002, 17, 403–407.
15 Some pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) such us DC-81,
tomamycin and anthramycin are naturally occurring anticancer an-
tibiotics produced by some species of Streptomyces bacteria. See: (a) A.
Kamal, D. Rajender, D. R. Reddy, M. K. Reddy, G. Balakishan, T. B.
Shaik, M. Chourasia and G. N. Sastry, Bioorg. Med. Chem., 2009, 17,
1557–1572; (b) W. P. Hu, J. J. Liang, Ch. L. Kao, Y. Ch. Chen, Ch. Y.
Chung, F. Y. Tsai, M. J. Wu, L. S. Chang, Y. L. Chen and J. J. Wang,
Bioorg. Med. Chem., 2009, 17, 1172–1182.
28 This tandem has been successfully applied by our group to the synthesis
of different heterocycles. See for example: (a) E. Dom´ınguez, E.
Ibeas, E. Martinez de Marigorta, J. K. Palacios and R. SanMartin,
J. Org. Chem., 1996, 61, 5435–5439; (b) R. Olivera, R. SanMartin,
F. Churruca and E. Dom´ınguez, J. Org. Chem., 2002, 67, 7215–7225;
(c) S. Herna´ndez, R. SanMartin, I. Tellitu and E. Dom´ınguez, Org.
Lett., 2003, 5, 1095–1098.
29 (a) V. T. Bandurco, C. F. Schewender, S. C. Bell, D. W. Combs, R. M.
Kanojia, S. D. Levine, D. M. Mulvey, M. A. Appollina, M. S. Reed,
E. A. Malloy, R. Falotico, J. B. Moore and A. J. Tobia, J. Med. Chem.,
1987, 30, 1421–1426; (b) G. Broggini, L. Garanti, G. Molteni, T. Pilati,
A. Ponti and G. Zecchi, Tetrahedron: Asymmetry, 1999, 10, 2203–2212.
2256 | Org. Biomol. Chem., 2011, 9, 2251–2257
This journal is
The Royal Society of Chemistry 2011
©